Drug intelligence / Profile preview

simethicone + pronase

Development stage: Unknown
Lead developer: GSK
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

A combination premedication used before upper gastrointestinal endoscopy procedures to improve mucosal visibility. Simethicone acts as a defoaming agent that reduces gas bubbles, while pronase functions as a mucolytic enzyme that breaks down mucus in the stomach. Together, they significantly enhance the clarity of the endoscopic visual field, which can improve diagnostic accuracy and potentially increase the detection of early cancers and precancerous lesions.

Beyond the preview

Go deeper on simethicone + pronase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simethicone + pronase.

Explore the full profile